Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the α-fetoprotein promoter enhancer and pgk promoter: an in vitro and in vivo study

Figure 1

Inhibition of PP2A induces cytotoxic effects. (A) The MTT assay revealed that the PP2A inhibitor cantharidin repressed cell viability in a dose- and time-dependent manner. (B) Sequencing of PP2Acα and DN-PP2Acα. DN-PP2Acα was generated from WT-PP2Acα using site-directed mutagenesis to mutate Leu 199 into Pro. (C) The serine/threonine phosphatase assay and MTT assay showed that overexpression of DN-PP2Acα repressed the activity of PP2A and reduced cell viability 48 h after transfection; *P < 0.05 and **P < 0.01 compared to the respective control groups.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us